 Guardant Health Inc NASDAQ:GH stock plunged on Friday after the firm released results from a study of its colon cancer blood test that showed disappointing accuracy rates. Although the test accurately identified the presence of cancer or precancer 83 of the time, investors were hoping to see at least an 85 accuracy rate, Bloomberg reported. 